J&J's Children's Motrin to get advisory committee review.
This article was originally published in The Tan Sheet
Executive Summary
J&J's CHILDREN's MOTRIN TO GET ADVISORY COMMITTEE REVIEW as part of the Nonprescription Drugs Advisory Committee's agenda for its March 27-28 meeting. On the morning of March 28, NDAC with FDA's Arthritis Advisory Committee will consider J&J's application covering the OTC marketing of the pediatric ibuprofen suspension product.